Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

Robert Z. Orlowski, Philippe Moreau, R. Niesvizky, H. Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, A. S. Kimball, Meletios Dimopoulos

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups'. Together they form a unique fingerprint.

Medicine & Life Sciences